Daiichi Sankyo hones R&D focus on thrombosis and cancer
This article was originally published in Scrip
Executive Summary
Following the recent EU approval and positive US recommendation for the platelet inhibitor Effient (prasugrel), Daiichi Sankyo is focusing attention on its next promising cardiovascular product, edoxaban (DU-176b).